• Home
  • Who we are
    • Who We Are
    • Board of Directors
    • Management
    • Scientific Advisory Boards
    • Privacy Notice
  • Portfolio
    • Portfolio Overview
    • Diabetes
    • Oral delivery of peptides
  • Technology
  • Partnerships
  • Investors
    • Investor Centre
    • Regulatory News
    • Email alerts
    • Presentations
    • Financial Results
    • In the media
    • Shareholder Information
    • FAQs and help
    • AIM Rule 26
    • Corporate Governance
    • Advisors
    • Warning to shareholders
  • News & Events
    • News
    • Events
  • Careers
  • Contact us
Home / News / ARECOR ANNOUNCES PRESENTATION AT EASD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES

ARECOR ANNOUNCES PRESENTATION AT EASD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES

SCROLL DOWN
QUICK LINKS
  • Home
  • Who We Are
  • Our Portfolio
  • Our Technology
  • Partnerships
  • Investors
  • News
  • Careers
  • Contact Us
  • Privacy Notice
  • Disclaimer
FOLLOW US ON
Website designed by Carr Kamasa Design
Cookie Policy
Copyright Arecor © 2026.
Arecor® and Arestat® are registered trademarks of Arecor Limited

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Arecor
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Cookie Policy

More information about our Cookie Policy